cJun overexpression in MCF-7 breast cancer cells produces a tumorigenic, invasive and hormone resistant phenotype
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“c-Jun overexpression also greatly enhances the tumorigenic, invasive and hormone-resistant phenotype of the breast cancer cell line MCF7 (Smith et al ., 1999).”
From Pdcd4 suppresses tumor phenotype in JB6 cells by inhibiting AP-1 transactivation (2003) · cites this paper as Smith et al., 1999
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Yang-Yen, H.-F., Chambard, J.-C., Sun, Y.-L., Smeal, T., Schmidt, T. J., Drouin, J., & Karin, M. (1990) · Cell · doi:10.1016/0092-8674(90)90396-v · Cited by 1,553 · cited 1×
“Cross-talk between AP-1 and several steroid receptors such as estrogen receptor (ER), glucocorticoid and retinoic acid receptors can either enhance or repress AP-1 activity through direct or indirect protein ± protein interactions (Yang-Yen et al., 1990; Uht et al., 1997; Vig et al., 1994).”
BackgroundBohmann, D., Bos, T. J., Admon, A., Nishimura, T., Vogt, P. K., & Tjian, R. (1987) · Science · doi:10.1126/science.2825349 · Cited by 1,321 · cited 1×
“Keywords: cJun; AP-1; breast cancer; tumorigenicity; invasion; hormone resistance The proto-oncogene c-jun encodes a 39 kDa nuclear phosphoprotein, cJun, which is a component of the mammalian transcription factor activator protein-1 (AP-1) (Bohmann et al., 1987; Angel et al., 1988).”
BackgroundSelf-citationOncogene jun encodes a sequence-specific trans- activator similar to AP-1
Angel, P., Allegretto, E. A., Okino, S. T., Hattori, K., Boyle, W. J., Hunter, T., & Karin, M. (1988) · Nature · doi:10.1038/332166a0 · Cited by 907
Dong, Z., Birrer, M. J., Watts, R. G., Matrisian, L. M., & Colburn, N. H. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.2.609 · Cited by 386 · cited 1×
“The role of cJun in cellular transformation has been de®ned previously in rodent and avian model systems (Vogt et al., 1990; Suzuki et al., 1991; Castellazzi et al., 1990, Dong et al., 1994).”
BackgroundSelf-citation
Cited by
Manna, S. K., Mukhopadhyay, A., & Aggarwal, B. B. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.12.6509 · Cited by 879
Cellular and Molecular Pharmacology of Antiestrogen Action and Resistance
Clarke, R., Leonessa, F., Welch, J. N., & Skaar, T. C. (2001) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01479-0 · Cited by 397
Molecular mechanisms of resistance to CDK4/6 inhibitors in breast cancer: A review
Pandey, K., An, H., Kim, S. K., Lee, S. A., Kim, S., Lim, S. M., Kim, G. M., Sohn, J., & Moon, Y. W. (2019) · International Journal of Cancer · doi:10.1002/ijc.32020 · Cited by 361
Lombaerts, M., van Wezel, T., Philippo, K., Dierssen, J. W. F., Zimmerman, R. M. E., Oosting, J., van Eijk, R., Eilers, P. H., van de Water, B., Cornelisse, C. J., et al. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6602996 · Cited by 346
The biological role of estrogen receptors α and β in cancer
Pearce, S. T., & Jordan, V. C. (2004) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2003.09.003 · Cited by 311
Small Molecule Inhibitors Targeting Activator Protein 1 (AP-1): Miniperspective
Ye, N., Ding, Y., Wild, C., Shen, Q., & Zhou, J. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm5004733 · Cited by 307
Vogt, P. K. (2001) · Oncogene · doi:10.1038/sj.onc.1204443 · Cited by 289
McClelland, R. A., Barrow, D., Madden, T., Dutkowski, C. M., Pamment, J., Knowlden, J. M., Gee, J. M. W., & Nicholson, R. I. (2001) · Endocrinology · doi:10.1210/en.142.7.2776 · Cited by 258
Dechow, T. N., Pedranzini, L., Leitch, A., Leslie, K., Gerald, W. L., Linkov, I., & Bromberg, J. F. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0404100101 · Cited by 254
Pdcd4 suppresses tumor phenotype in JB6 cells by inhibiting AP-1 transactivation
Yang, H.-S., Knies, J. L., Stark, C., & Colburn, N. H. (2003) · Oncogene · doi:10.1038/sj.onc.1206433 · Cited by 173
“Overexpression of human c-jun mRNA transforms immortalized fibroblast rat 1a cells and renders cells tumorigenic when injected into nude mice (Schutte et al., 1989a). c-Jun overexpression also greatly enhances the tumorigenic, invasive and hormone-resistant phenotype of the breast cancer cell line MCF7 (Smith et al.,…”
BackgroundCAPER, a novel regulator of human breast cancer progression
Mercier, I., Gonzales, D. M., Quann, K., Pestell, T. G., Molchansky, A., Sotgia, F., Hulit, J., Gandara, R., Wang, C., Pestell, R. G., et al. (2014) · Cell Cycle · doi:10.4161/cc.28156 · Cited by 45
“For instance, overexpression of c-Jun was shown to increase the tumorigenic and invasive potentials of MCF-7 cells in both in vitro and in vivo settings.(47) Conversely, inhibition of AP-1/c-Jun transcriptional activity in MCF-7 cells through expression of a c-Jun dominant-negative mutant (Tam67) was shown to suppress…”
BackgroundSchwessinger, R., Suciu, M. C., McGowan, S. J., Telenius, J., Taylor, S., Higgs, D. R., & Hughes, J. R. (2017) · Genome Research · doi:10.1101/gr.220202.117 · Cited by 35
(2000) · doi:10.1002/1097-0215(20001015)88:2<157::aid-ijc2>3.0.co;2-b
Metadata
- Authors
- Smith, L. M., Wise, S. C., Hendricks, D. T., Sabichi, A. L., Bos, T., Reddy, P., Brown, P. H., & Birrer, M. J.
- Venue
- Oncogene
- Published
- 1999-10-26
- Volume
- 18
- Issue
- 44
- Pages
- 6063-6070
- ISSN
- 0950-9232 (ISSN-L)
- 1476-5594
- OpenAlex
- W2013535202
- Cited by
- 213
- References
- 4
- FWCI
- 4.05
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.